Bezwoda W R, Hesdorffer C S
Cancer. 1986 Jan 15;57(2):218-21. doi: 10.1002/1097-0142(19860115)57:2<218::aid-cncr2820570205>3.0.co;2-j.
Fifty patients with Stage IV breast cancer were entered into a prospective Phase II trial of combination chemotherapy that consisted of mitoxantrone (10 mg/m2), methotrexate (40 mg/m2), and 5-fluorouracil (600 mg/m2) given in a 3-weekly schedule. Objective response to treatment was seen in 18 of 48 assessable patients (38%). Responses were seen predominantly in the lung and pleura and the node and soft tissue sites of disease. The median duration of response was 7 months. Toxicity from treatment consisted predominantly of reversible leukopenia. Other toxicities such as nausea and alopecia occurred in less than one half of the patients in the study group. The combination was well-tolerated, and appears to be moderately effective.
五十名IV期乳腺癌患者进入了一项前瞻性II期联合化疗试验，该化疗方案包括米托蒽醌（10mg/m²）、甲氨蝶呤（40mg/m²）和5-氟尿嘧啶（600mg/m²），每三周给药一次。48名可评估患者中有18名（38%）出现了客观治疗反应。反应主要出现在肺和胸膜以及疾病的淋巴结和软组织部位。反应的中位持续时间为7个月。治疗毒性主要为可逆性白细胞减少。研究组中不到一半的患者出现了恶心和脱发等其他毒性反应。该联合方案耐受性良好，似乎有中等疗效。
